Gene Therapy Sparks Significant Factor IX Activity in 10 Men With Hemophilia B

Share this post

Experimental gene therapy designed to restore production of factor IX has left all 10 hemophiliac volunteers without the need for baseline prophylaxis and halted nearly all excess bleeding, according to a December 6 online report of a small phase 1-2a study in The New England Journal of Medicine.
Reuters Health Information

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply